Navigation Links
Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors
Date:8/29/2014

BOSTON, Aug. 29, 2014 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostics medical device company based in Boston announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company's Board of Directors.

"Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital," said Remis Bistras, President and CEO of Vittamed. "We are extremely delighted to add his clinical, strategic, and entrepreneurial expertise to our Board."

Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen's University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons.  He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds.  

"I am honored to join Vittamed at this exciting time in its history," said Dr. Dagi.  "With the recent CE mark approval for both its products and multiple near-term commercial opportunities, I look forward to helping Vittamed achieve its mission of delivering non-invasive neuromonitoring and diagnostics to patients with unmet medical needs."

He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen's University Belfast for contributions to medicine and public service. 

About Vittamed
Vittamed is a Boston-based company with R&D operations in Lithuania. Using ultrasound based technology, it has developed a suite of clinically proven and validated devices.  The Vittamed 205 is a non-invasive Intracranial Pressure (ICP) meter and the Vittamed 505 is a non-invasive Cerebrovascular Perfusion and Autoregulation monitoring device.  Multiple prospective clinical trials with several hundred patients have proven that the Vittamed devices deliver reliable, clinically acceptable, accurate and precise results as compared to today's standard of care using invasive intraventricular and lumbar puncture ICP measurements.  Recently Vittamed received CE mark for its both devices and is preparing for commercialization in the EU as well as 510 (k) filing in the US.

For more information, please visit www.vittamed.com


'/>"/>
SOURCE Vittamed Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
2. Meditope Biosciences Appoints Prominent Scientific Advisory Board
3. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
4. Sanomedics Signs Definitive Agreement for Acquisition of a prominent Texas based Sleep Services company.
5. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
6. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
7. La Jolla Neurosurgeon Introduces Cutting-Edge Surgery for Scoliosis Patients
8. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
9. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
10. Vivex Biomedical and Akron Biotech: Collaborative Venture in Regenerative Medicine
11. Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):